Log in

Adaptimmune Therapeutics Earnings Date, Estimates & History

-0.02 (-0.44 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $4.51
50-Day Range
MA: $7.62
52-Week Range
Now: $4.51
Volume1.15 million shs
Average Volume1.54 million shs
Market Capitalization$586.80 million
P/E RatioN/A
Dividend YieldN/A


Adaptimmune Therapeutics (NASDAQ:ADAP) Earnings Information

Adaptimmune Therapeutics last released its quarterly earnings results on August 6th, 2020. The biotechnology company reported ($0.24) earnings per share for the quarter, hitting the consensus estimate of ($0.24). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.95 million. Adaptimmune Therapeutics has generated ($1.32) earnings per share over the last year. Adaptimmune Therapeutics has confirmed that its next quarterly earnings report will be published on Thursday, November 5th, 2020. Adaptimmune Therapeutics will be holding an earnings conference call on Thursday, November 5th. Interested parties can register for or listen to the call using this link.

Adaptimmune Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Adaptimmune Therapeutics (NASDAQ:ADAP) Earnings Estimates

2020 EPS Consensus Estimate: ($0.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20201$0.12$0.12$0.12
Q2 20201($0.36)($0.36)($0.36)
Q3 20201($0.36)($0.36)($0.36)
Q4 20201($0.36)($0.36)($0.36)

Adaptimmune Therapeutics (NASDAQ ADAP) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
 ($0.23)    Register (Before Market Opens)
8/6/20206/30/2020($0.24)($0.24)($0.24)$0.95 million$0.50 millionListen
5/14/2020Q1($0.25)($0.24)($0.24)$25.90 million$0.76 millionTranscript
2/27/2020Q4 2019($0.33)($0.28)($0.28)$3.60 million$0.73 millionN/A
11/6/2019Q3($0.33)($0.36)($0.37)$7.00 million$0.24 millionListen
8/1/2019Q2 2019($0.35)($0.42)($0.42)$4.25 million$0.16 millionTranscript
5/6/2019Q1 2019($0.28)($0.24)($0.24)$1.50 millionN/A
2/27/2019Q4 2018($0.29)($0.36)($0.36)$14.50 million$1.48 millionN/A
11/6/20189/30/2018($0.03)$0.06$0.05$29.41 million$40.79 millionN/A
8/2/20186/30/2018($0.28)($0.48)($0.48)$7.76 million$9.04 millionN/A
5/9/2018Q1 2018($0.24)($0.04)($0.24)$7.59 million$8.20 millionN/A
3/15/2018Q4 2017($0.25)($0.29)($0.29)$9.38 million$4.27 millionN/A
8/3/20176/30/2017($0.24)($0.24)($0.24)$5.43 million$3.52 millionN/A
5/10/20173/31/2017($0.24)($0.30)($0.30)$5.07 million$2.86 millionN/A
3/13/201712/31/2016($0.27)($0.22)($0.22)$3.98 million$8.54 millionN/A
11/10/2016Q3 2016($0.27)($0.24)($0.24)$6.08 million$2.42 millionN/A
8/8/2016Q2 2016($0.22)($0.31)($0.31)$4.75 million$0.33 millionN/A
5/12/2016Q1 2016($0.22)($0.04)($0.04)$7.11 million$2.92 millionN/A
3/17/2016Q4 2015($0.14)($0.13)($0.13)$2.00 million$4.18 millionN/A
11/13/2015Q3 2015($0.23)($0.02)($0.02)$3.93 millionN/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.